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Impaired mitochondrial calcium efflux contributes
to disease progression in models of Alzheimer’s
disease
Pooja Jadiya 1, Devin W. Kolmetzky1, Dhanendra Tomar 1, Antonio Di Meco1,2, Alyssa A. Lombardi1,
Jonathan P. Lambert 1, Timothy S. Luongo1, Marthe H. Ludtmann3, Domenico Praticò1,2 & John W. Elrod 1
Impairments in neuronal intracellular calcium (iCa2+) handling may contribute to Alzheimer’s
disease (AD) development. Metabolic dysfunction and progressive neuronal loss are asso-
ciated with AD progression, and mitochondrial calcium (mCa2+) signaling is a key regulator
of both of these processes. Here, we report remodeling of the mCa2+ exchange machinery in
the prefrontal cortex of individuals with AD. In the 3xTg-AD mouse model impaired mCa2+
efflux capacity precedes neuropathology. Neuronal deletion of the mitochondrial Na+/Ca2+
exchanger (NCLX, Slc8b1 gene) accelerated memory decline and increased amyloidosis and
tau pathology. Further, genetic rescue of neuronal NCLX in 3xTg-AD mice is sufficient to
impede AD-associated pathology and memory loss. We show that mCa2+ overload con-
tributes to AD progression by promoting superoxide generation, metabolic dysfunction and
neuronal cell death. These results provide a link between the calcium dysregulation and
metabolic dysfunction hypotheses of AD and suggest mCa2+ exchange as potential ther-
apeutic target in AD.
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A lzheimer’s disease (AD) is an age-associated multifactorialdisease characterized by two major pathological hall-marks, senile plaques composed of extracellular β-
amyloid (Aβ) and neurofibrillary tangles (NFTs) composed of
hyperphosphorylated tau. These protein aggregates are thought to
trigger neurodegeneration, resulting in loss of memory and cog-
nitive skills in both sporadic and familial forms of AD1. Over the
past two decades, there has been progress in identifying various
cellular mechanisms contributing to AD pathogenesis, but at
present the underlying cause is unknown and thus far therapeutic
strategies targeting Aβ and tau pathways have failed2,3.
It is widely accepted that intracellular calcium (iCa2+) signaling
has an essential role in synaptic transmission and neuronal intra-
and paracellular communication. The majority of neuronal ATP
is consumed to modulate ion flux at the plasma membrane and
ER to control iCa2+ levels4.
Given the essential nature of Ca2+ regulation to cellular
homeostasis, it is not surprising that alterations in Ca2+ handling
have been reported to be a central feature of neurodegeneration
and age-related diseases5. Numerous reports of Ca2+ dysregula-
tion coalesced into the formation of the “calcium hypothesis of
aging and AD”6,7. The calcium hypothesis theorizes that altera-
tions in Ca2+ handling, leading to elevations in iCa2+, are a
central mechanism linking amyloid metabolism to neuronal cell
death and cognitive decline. Indeed, numerous molecular
mechanisms have been shown to contribute to amyloid-mediated
impairments in Ca2+ regulation at multiple cellular levels
including: altered SERCA activity, increased ryanodine receptor
leak8, and increased inositol 1,4,5-trisphosphate receptor activity
at the ER9, the dysregulation of voltage-operated channels such as
calcium homeostasis modulator 110, altered receptor-dependent
Ca2+ signaling (nicotinic acetylcholine receptors, N-methyl-D-
aspartate receptors7 and amino-3-hydroxy-5-methyl-4-iso-
xazolepropionic acid receptors11 and the dysregulation of store-
operated calcium entry at the plasma membrane12. Inversely,
there is growing evidence that Ca2+ dysregulation is upstream in
the disease process and perhaps precede amyloidogenic disease.
This has prompted some investigators to propose that impair-
ments in Ca2+ regulation may actually drive AD
development13,14. Regardless, there is clear evidence of Ca2+
dysregulation with numerous studies suggesting neurons are
subjected to elevated iCa2+ levels in AD.
This increase in iCa2+ coupled with alterations in ER/mito-
chondria tethering,15,16 is theorized to cause mitochondrial cal-
cium (mCa2+) overload, which is linked to: excessive reactive
oxygen species (ROS) generation, metabolic derangement, and
mitochondrial dysfunction, all prominent features of AD patho-
genesis. In addition, it is widely recognized that mCa2+ can
directly influence cell death signaling by activating the mito-
chondrial permeability transition pore and Ca2+ dependent
proteases (calpains), and indirectly through its effects on super-
oxide generation and ATP availability17–20. Although several
studies have proposed that mitochondrial dysfunction is a pri-
mary trigger for AD development17,21 to date no causal studies
have directly implicated alterations in mCa2+ exchange with AD
or examined the direct contribution of mCa2+ signaling with
disease progression.
The mitochondrial Na+/Ca2+ exchanger (NCLX) is the pri-
mary mechanism for mCa2+ efflux in excitable cells22,23, and
thereby is an excellent target to modulate mCa2+ load in neurons.
Here, we provide evidence that mCa2+ efflux is impaired in an
age-dependent fashion in multiple experimental models of AD
and that NCLX expression is lost in the frontal cortex of non-
familial/sporadic AD patients. Our data suggest that the dysre-
gulation of mitochondrial calcium efflux precedes neuropathol-
ogy and memory decline in AD. We propose that these results
provide a missing link between the “calcium dysregulation” and
“mitochondrial dysfunction” hypotheses and advocate targeting
mitochondrial calcium exchange as a powerful therapeutic to
inhibit or reverse AD progression.
Results
Loss of NCLX expression correlates with AD progression.
Frontal cortex samples were collected postmortem from non-
familial, sporadic AD patients, and age-matched controls with no
history of dementia and probed for alterations in the expression
of mitochondrial calcium handling genes. Interestingly, we
observed a substantial reduction in the expression of NCLX, the
primary mediator of mCa2+ efflux in excitable cells (Fig. 1a). In
addition, we observed a reduction in the mitochondrial calcium
uniporter channel (mtCU)-associated proteins: MICU1 and
MCUB. The voltage-dependent anion channel (VDAC) and
Complex V-Sα (CV-Sα) served as mitochondrial loading controls.
Next, we examined mCa2+ transporter expression in a well
characterized, robust murine model of AD to determine whether
these alterations preceeded or coincided with neurohistopathol-
ogy and behavior deficits. We acquired mutant mice harboring
three gene mutations associated with familial AD (3xTg-AD):
Presenilin 1 (Psen1, M146V homozygous knock-in), amyloid beta
precursor protein (APPswe, KM670/671NL transgene) and
microtubule associated protein tau (MAPT, P301L transgene).
These mice develop age-progressive pathology similar to that
observed in AD patients including: impaired synaptic transmis-
sion, Aβ deposition, plaque/tangle histopathology, and learning/
memory deficits beginning ~6 months of age24. mRNA and
protein were isolated from brain tissue derived from the frontal
cortex and hippocampus of 2, 4, 8, and 12-month-old 3xTg-AD
mutant mice and outbred age-matched, non-transgenic controls.
3xTg-AD mice displayed an age-dependent reduction in NCLX
expression with a significant decrease noted as early as 4 months
and near complete loss of mRNA and protein by 12 months of
age (Fig. 1b, c; Supplementary Fig. 1A–D). Importantly, we found
no significant alteration in the expression of any transporters
associated with mCa2+ exchange in samples isolated from the
brains of 2-month-old 3xTg-AD mice, an age prior to any
detectable neuropathology or memory deficits25 (Fig. 1b; Sup-
plementary Fig. 1a, e). These results suggest the changes in gene
expression are age-dependent and not merely the result of
developmental expression changes associated with this mutant
model. The loss of the key mCa2+ efflux mediator, NCLX, and
decrease in the expression of negative regulators of the mtCU,
MICU1 (gatekeeper of mtCU to limit uptake at low iCa2+ and
augmenter of uptake at high iCa2+ levels26–29) and MCUB30, is
likely to promote increased [mCa2+] levels; especially in the high
iCa2+ environment that is reported to occur in neurons during
AD progression6. These alterations are in stark contrast to the
compensatory alterations we have previously reported in cardiac
biopsies isolated from failing hearts at the time of transplant22,
and suggest that in AD, changes in the expression profile of
mCa2+ transporters may contribute to matrix Ca2+ overload and
disease development.
Rescue of NCLX expression corrects impairments in mCa2+
exchange. Next, we moved to a system more amendable to real-
time mechanistic studies and employed a neuroblastoma cell line
(N2a) stably expressing the familial APPswe mutation (K670N,
M671L, APPswe31) coupled with a neuronal maturation proto-
col32. Surprisingly, maturated APPswe cells also displayed a sig-
nificant reduction in the expression of NCLX, mirroring the
results obtained from human AD brains (Fig. 1d, e). No change
in VDAC or OxPhos component expression was observed,
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suggesting no change in overall mitochondrial content (Fig. 1e;
Supplementary Fig. 1F). To evaluate if restoring NCLX expression
was sufficient to rescue impairments in mCa2+ handling we
infected APPswe cells with adenovirus encoding NCLX (Ad-
NCLX). The decrease in NCLX expression in APPswe cells was
completely rescued 48 h post transduction with Ad-NCLX
(Fig. 1d, e). To evaluate if the alterations in mCa2+-associated
gene expression impacted intracellular Ca2+ handling we exam-
ined cCa2+ and mCa2+ transients. Neurons were transduced with
adeno-associated virus encoding the mitochondrial-targeted Ca2+
reporter, R-GECO1 (AAV6-mitoR-GECO) and loaded with the
cCa2+ reporter, Fluo4-AM and imaged continuously during sti-
mulation with KCl to induce plasma membrane depolarization
and activation of voltage-gated Ca2+ channels (Fig. 1f, i). APPswe
cells displayed a significant increase, ~40%, in mCa2+-transient
peak amplitude as compared to N2a control cells, and this was
significantly reduced by rescuing NCLX expression (Fig. 1g).
Quantification of the mCa2+ efflux rate revealed ~60% decrease in
APPswe cells, as compared with N2a con cells, and infection with
Ad-NCLX significantly restored the efflux rate (Fig. 1h). Mea-
surements of cCa2+ flux confirmed elevated cCa2+ levels in
APPswe cells, which was not impacted by rescuing NCLX
expression (Fig. 1j; Supplementary Fig. 1H, I). To evaluate if
impaired mCa2+ efflux may contribute to mCa2+ overload, we
measured the mCa2+ retention capacity using the ratiometric
reporters FuraFF, to monitor Ca2+, and JC1, to monitor mito-
chondrial membrane potential, Δψ (Supplementary Fig. 1J–M).
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Time (s)
cC
a2
+  
(F
/F0
)
0 100 200 300 400 500
0
1
2
3
4 Con
APPswe
APPswe + Ad-NCLX
KCl
Con + Ad-NCLX
NCLX
Co
n
AP
Ps
we
AP
Ps
we
+ 
Ad
-N
CL
X
Co
n
+ 
Ad
-N
CL
X
VDAC
Tubulin~50 kD
~30 kD
~64 kD
lkji
ba dc
hfe
m
Con
APPswe + Ad-NCLX
APPswe
Con + Ad-NCLX
Time (s)
m
Ca
2+
 (F
/F0
)
0 100 200 300 400 500
0
1
2
3
4 KCl
Con
APPswe + Ad-NCLX
APPswe
Con + Ad-NCLX
0 100 200 300 400 500
0.5
1.0
1.5
2.0
Time (s)
M
at
rix
 fr
ee
-C
a2
+
 
fu
ra
2 
(R
/R
0)
FCCP
Con
APPswe + Ad-NCLX
APPswe
Con + Ad-NCLX
12 mo. old
MCU
MCUB
MICU1
MICU2
EMRE
NCLX
VDAC
CV-Sα
~34 kD
~48 kD
~64 kD
~16 kD
~30 kD
~55 kD
~35 kD
~50 kD
NTg con 3xTg-AD
MCU
MCUB
MICU1
MICU2
EMRE
NCLX
VDAC
CV-Sα
~34 kD
~48 kD
~64 kD
~16 kD
~30 kD
~55 kD
~35 kD
~50 kD
Age-matched 
controls
Non-familial 
AD
2 4 8 12
0
25
50
75
100
125
150
N
CL
X 
m
RN
A
(%
 ch
an
ge
 vs
. c
on
)
NTg con
3xTg-AD
Months
*
*
*
N
CL
X 
m
RN
A
(%
 ch
an
ge
 vs
. c
on
)
0
50
100
150
200
**
**
**
****
Con
Con + Ad-NCLX
APPswe
APPswe + Ad-NCLX
Con
Con + Ad-NCLX
APPswe
APPswe + Ad-NCLX ConCon + Ad-NCLX
APPswe
APPswe + Ad-NCLX
m
Ca
2+
 
e
ffl
ux
 ra
te
 
(%
 vs
. c
on
)
0
20
40
60
80
100
120
140
****
****
* **
cC
a2
+ 
a
m
pl
itu
de
0
1
2
3
***
****
Con
Con + Ad-NCLX
APPswe
APPswe + Ad-NCLX
0
20
40
60
80
100
120
m
ito
-C
RC
(%
 ch
an
ge
 vs
. c
on
)
*
**
**
Con
Con + Ad-NCLX
APPswe
APPswe + Ad-NCLX
Con
Con + Ad-NCLX
APPswe
APPswe + Ad-NCLX
m
Ca
2+
 a
m
pl
itu
de
0
1
2
3
****
***
***
g
0
50
100
150
200
M
at
rix
 fr
ee
-C
a2
+
(%
 ch
an
ge
 vs
. c
on
)
*
**
n 0 400 800 1200
0
1
2
3
4
Time (s)
Fu
ra
-F
F 
(R
/R
0)
Ca2+ :
FCCP
Fig. 1 NCLX expression and mtCU components are significantly altered in AD. a Western blots for proteins associated with mCa2+ exchange in
postmortem brains of patients diagnosed with non-familial, sporadic AD, and age-matched controls, n= 7 for both groups. MCU, Mitochondrial Calcium
Uniporter; MCUB, Mitochondrial Calcium Uniporter β-subunit; MICU1, Mitochondrial Calcium Uptake 1; MICU2, Mitochondrial Calcium Uptake 2; EMRE,
Essential MCU Regulator; NCLX, Mitochondrial Na+/Ca2+ Exchanger. Voltage-dependent anion channel (VDAC) and oxidative phosphorylation
component, Complex V α-subunit (CV-Sα) were used as mitochondrial loading controls. b NCLX mRNA expression in tissue isolated from the frontal
cortex of 3xTg-AD mutant mice and age-matched outbred non-transgenic controls (NTg). c Western blots for expression of mCa2+ exchanger in 12-
month-old 3xTg-AD mutant mice and age-matched NTg controls, n= 3 for both groups. d NCLX mRNA expression in N2a control+Ad-NCLX, APPswe
and APPswe+Ad-NCLX corrected to N2a control. e Western blots for NCLX expression in N2a control, Control+Ad-NCLX, APPswe, and APPswe+Ad-
NCLX; representative of three independent experiments. fMitochondrial Ca2+ transients, mean shown as solid line, thin lines display ± SEM; n= 9 for Con,
n= 9 for Con+Ad-NCLX, n= 11 APPswe and n= 9 for APPswe+Ad-NCLX. g Quantification of mCa2+ transient peak amplitude. h Percent mCa2+ efflux
rate vs. control. i Cytosolic Ca2+ transients, mean shown as solid line, thin lines display ± SEM. j Quantification of cytosolic Ca2+ peak amplitude.
k Representative recordings of mitochondrial Ca2+ retention capacity. l Percent change in mCa2+ retention capacity vs. N2a control cells. m Representative
traces for basal mitochondrial Ca2+ content. n Quantification of mCa2+ content. (n= individual dots shown for each group in all graphs. All data presented
as mean ± SEM; ****p < 0.001, **p < 0.01, *p < 0.05; one-way ANOVA with Sidak's multiple comparisons test.) Source data are available as a Source
Data file
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10 µM delivery of bath Ca2+, Fig. k, l). This was in striking
contrast to control cells, which sustained three-times the con-
centration of bath Ca2+ before collapse of Δψ and loss of matrix
Ca2+. Rescue of NCLX expression in APPswe neurons greatly
increased the mitochondrial calcium retention capacity (CRC;
~9th 10 µM bath Ca2+ injection, Fig. 1k, l). To evaluate if
restoring NCLX-mediated efflux was sufficient to reduce matrix
Ca2+ load, cells were loaded with Fura2 and treated with digi-
tonin to permeabilize the plasma membrane and thapsigargin to
inhibit SERCA, followed by treatment with FCCP to release all
free-Ca2+ from the mitochondrial matrix20. Quantification of
mCa2+ content found that NCLX expression completely corrected
APPswe-mediated Ca2+ overload (Fig. 1m, n). In summary,
AD-like stress is associated with a severe impairment in mCa2+
efflux capacity and predisposition to mCa2+-overload and per-
meability transition.
Loss of neuronal NCLX accelerates AD progression. To define
whether impaired mCa2+ efflux causally contributes to the pro-
gression of AD, NCLX conditional mutant mice (Slc8b1fl/fl,
denoted as NCLXfl/fl)22 were crossed with a neuronal-restricted
Cre recombinase transgenic model (Camk2a-Cre) to delete NCLX
from the forebrain, specifically the prefrontal cortex and CA1
pyramidal cell layer in the hippocampus33. The resultant
neuronal-specific NCLX conditional knockouts (NCLXfl/fl ×
Camk2a-Cre, NCLX-cKO) were backcrossed into the 3xTg-AD
mutant mouse background (NCLX-cKO mice × 3xTg-AD,
Fig. 2a). qPCR analysis of NCLX mRNA expression found ~75%
loss of NCLX in the frontal cortex of 2-month-old NCLX-cKO ×
3xTg-AD mice (Fig. 2b) and a corresponding reduction in hip-
pocampal NCLX protein expression in 2, 9, and 12-month-old
mice (Fig. 2c; Supplementary Fig. 7N–P). No changes in the
expression of other proposed mCa2+ regulators were observed
(Supplementary Fig. 2A–C and Supplementary Fig. 7Mm’–Xx’).
Spatial learning and memory, was examined at 2, 6, 9, and
12 months of age using the Y-maze spontaneous alteration test34.
Loss of neuronal NCLX greatly accelerated 3xTg-AD-associated
impairments in spatial working memory as early as 6 months,
which continued out to 12 months of age (Fig. 2d; Supplementary
Fig. 2D). The total number of arm entries was not different
between groups, suggesting these cognitive impairments were not
owing to decreased fitness or motor function (Fig. 2e; Supple-
mentary Fig. 2E). To further examine learning memory, we
performed an automated contextual and cued fear-conditioning
test commonly used to evaluate fear learning and memory34,35.
Freezing behavior (complete immobility in this assay), is a
common response to fearful situations. After animals experience
pairing of an auditory cue with an electric footshock, the fear-
producing stimulus results in freezing behavior, assessed as an
index of associative fear learning and memory36. Freezing during
the training session was equivalent among all groups, suggesting
normal motor function (Fig. 2f; Supplementary Fig. 2F). Pro-
gressive impairments in contextual recall were noted in the 3xTg-
AD mice from 9 to 12 months of age and deletion of neuronal
NCLX potentiated this impairment in 12-month-old 3xTg-AD
mice (Fig. 2g; Supplementary Fig. 2G). Impairments in cued recall
were more substantial in NCLX-cKO × 3xTg-AD mice, which
displayed a 50% reduction at 6 months of age, well before any
decline was noted in 3xTg-AD mice. Cued recall continued to
decline at an accelerated rate in NCLX-null mice out to
12 months of age (Fig. 2h; Supplementary Fig. 2H). This is
intriguing as a deficit in cued recall is becoming clinically
accepted as a sensitive indicator and predictor of dementia37.
Intense research effort has been placed on identifying the link
between Ca2+ dysregulation and the amyloidogenic pathway38.
Studies have suggested Aβ increases iCa2+ levels by numerous
mechanisms and that vice versa39, increased iCa2+ augments Aβ
production and tau hyperphosphorylation, two hallmarks of AD.
To examine the effect of neuronal genetic loss of mCa2+efflux on
Aβ formation in vivo, we measured the concentrations of soluble
and insoluble Aβ1–40 and Aβ1–42 peptides in frontal cortex
homogenates by ELISA. NCLX-cKO × 3xTg-AD mice brains
displayed a significant increase in radio immunoprecipitation
assay (RIPA) buffer -soluble Aβ1–40 (~80%), Aβ1–42 (~60%), and
the Aβ1–42/1–40 ratio, as well as enhanced levels of insoluble
Aβ1–40 (~75%) and Aβ1–42 (~85%) (Fig. 2i, j; Supplementary Fig.
2I). Immunohistochemistry identified amyloid deposits through-
out the cerebral cortex and hippocampus of 3xTg-AD mice at
12 months of age and loss of neuronal NCLX increased the
amyloid plaque burden by ~60% (Fig. 2k, l). To assess Aβ
production and processing we checked the expression of Aβ
precursor protein (APP), and various proteases involved in APP
metabolism. We did not observe any changes in prefrontal cortex
expression of total APP, α-secretase (ADAM-10), or γ-secretase
complex components (presenilin 1, PS1; APH1 subunit; and
nicastrin) between 3xTg-AD brains and NCLX-cKO × 3xTg-AD
samples. However, we did observe a significant increase in β-
secretase (BACE1) expression with loss of NCLX expression in
the 3xTg-AD background (Fig. 2m; Supplementary Fig. 7S). Beta-
secretase is the rate-limiting enzyme in Aβ production40 and
increased levels and activity of BACE1 protein are found in the
brains of sporadic41 and familial AD patients42.
We next examined tau pathology, which is a pathological
hallmark of AD and prominent in our mutant AD mouse model.
Hyperphosphorylated tau forms insoluble aggregates that pro-
mote NFTs. The expression of total tau (soluble vs. insoluble) and
tau phosphorylation at several epitopes in prefrontal cortex
samples was evaluated by western blot and immunohistochem-
istry. Although phosphorylation was found to be elevated at all
the tau residues examined in 3xTg-AD brains, we only found
differential phosphorylation with the AT8 antibody (tau S202/
T205) in addition to a significant increase in the total levels of
insoluble tau in NCLX-cKO × 3xTg-AD brain homogenates
(Fig. 2n; Supplementary Fig. 7X–C’). Consistent with the
immunoblot results, HT7 total soluble-tau staining was not
different between groups (Fig. 2o, p); while, AT8 (tau S202/T205)
staining recapitulated the increase in phosphorylation observed
by western blot (Fig. 2o, q). In summary, these results suggest that
the loss of mCa2+ efflux capacity during AD progression
accelerates impairments in memory and increases Aβ plaque
burden, tau hyperphosphorylation and histopathology.
Rescue of neuronal NCLX expression prevents AD pathology.
To this point, our data suggest that mCa2+ overload may be a
contributing factor to AD progression, so we next examined if
enhancing mCa2+ efflux capacity would lessen disease burden.
We generated a neuronal-specific, doxycycline-controlled, mutant
mouse model to rescue NCLX expression, and function in the
3xTg-AD model (3xTg-AD × TRE-NCLX × Camk2a-tTA, Fig.
3a). To avoid developmental alterations in NCLX expression,
mice were maintained on doxycycline until 4 weeks of age, after
which it was removed to allow transgene activation. Camk2a-
tTA-driven expression increased neuronal hippocampal NCLX
mRNA and protein expression approximately twofold in 2 month
old mice compared with age-matched controls (Fig. 3b, c; Sup-
plementary Fig. 7D’) with no change in the expression of mtCU
components (Fig. 3c; Supplementary Fig. 7E’-G’). 3xTg-AD ×
NCLX-overexpressing mice and controls were evaluated for age-
dependent loss of cognitive function and memory in the Y-maze
and automated contextual and cued fear-conditioning tests.
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Strikingly, the rescue of neuronal NCLX expression completely
restored the age-associated cognitive decline of 3xTg-AD mice
(Fig. 3d-h). In fact, 3xTg-AD × NCLX-overexpressing mice were
no different from Camk2a-tTA controls in the number of
alterations in the Y-maze test (spatial memory) and in freezing
activity in relation to contextual and cued recall in the fear-
conditioning test at all ages (6–12 months). Importantly, TRE-
NCLX × Camk2a-tTA mice showed no baseline behavioral dif-
ferences when compared to Camk2a-tTA controls (Supplemen-
tary Fig. 3A–E). These results suggest that the rescue of mCa2+
efflux in the 3xTg-AD model is sufficient to suppress age-
associated cognitive decline, even at an advanced stage of AD-like
disease.
To evaluate if the protection against memory loss correlated
with changes in overt cellular pathology, we evaluated Aβ levels in
homogenates isolated from the frontal cortex. RIPA-soluble, and
insoluble Aβ1–40 levels were reduced by >50% in 3xTg-AD ×
NCLX-overexpressing mice and likewise Aβ1–42 levels were
significantly decreased, as compared with 3xTg-AD × Camk2a-
tTA mice (Fig. 3i, j). In correlation, amyloid plaque burden was
reduced (~50%) in the brains of 3xTg-AD × NCLX overexpressing
mice (Fig. 3k, l). An evaluation of Aβ production and proteolytic
processing revealed no difference in the expression of ADAM-10,
or components of the γ-secretase complex (Fig. 3m; Supplemen-
tary Fig. 7H’–M’). However, we did observe a reduction in BACE1
expression in prefrontal cortex samples isolated from 3xTg-AD ×
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NCLX-overexpressing mice as compared with AD mutant mouse
controls (Fig. 3m; Supplementary Fig. 7J’), a result that correlates
with our findings of increased BACE1 expression in the NCLX-
null AD model (Fig. 2m).
We next determined how the rescue of neuronal NCLX
impacted tau pathology. There was a marked reduction (~40%)
in total insoluble tau, as well as a significant decrease in phospho-
tau at S202/T205 (AT8 immunoreactivity) (Fig. 3n; Supplementary
Fig. 7P’-Q’). Phosphorylation of tau at Ser396 (PHF13), T181
(AT270), and T231/ S235 (AT180) residues were no different
between groups (Fig. 3n; Supplementary Fig. 7R’-T’). Immuno-
histochemistry results further supported our biochemical findings,
showing reduced levels (~50%) of phosphorylated tau at S202/
T205 in the brains of 3xTg-AD mice overexpressing NCLX
(Fig. 3o, q). We found no change in the somatodendritic labeling
of total soluble-tau in CA1 pyramidal neurons, as would be
expected in this model which features transgenic neuronal
overexpression of mutant tau (Fig. 3o, p). In summary, the
neuronal rescue of mCa2+ extrusion substantially reduced cognitive
impairments and cytopathology in a robust in vivo model of AD.
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Restoring NCLX expression improves mitochondrial function.
To define mechanistically how salvaging mCa2+ efflux and
reducing mCa2+ overload diminishes AD-associated pathology
we returned to our in vitro AD model and began probing for
known mCa2+-linked cellular processes including oxidative
phosphorylation (OxPhos), redox signaling, and cell death. Pre-
viously, metabolic regulation has been shown to have an
important role in age-associated diseases, such as AD43,44.
Maturated APPswe cells were monitored for changes in OxPhos
by measuring mitochondrial oxygen consumption rates (OCR) in
a Seahorse assay. The stable expression of mutant APPswe elicited
a significant decrease in basal respiration, ATP-linked respiration,
and spare respiratory capacity with an increase in proton leak, all
of which were rescued 48 h post NCLX expression (Fig. 4b–g).
NCLX expression in control cells had no effect on OCR. Given
the role of redox stress in AD pathology45,46 and its close asso-
ciation with mCa2+ overload47, coupled with the observation of
increased ETC proton leak we examined the extent of oxidative
stress. Thirty minutes following treatment with the Ca2+ iono-
phore, ionomycin, APPswe displayed an increase in total ROS
that was significantly reduced in APPswe cells expressing NCLX
(48 h post adeno) (Fig. 4h). Next, we employed the superoxide
probe, dihydroethidium (DHE), and found APPswe cells were
generating approximately fourfold more superoxide, which was
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significantly attenuated with the rescue of NCLX expression (Fig.
4i). To further define the subcellular source of ROS we measured
superoxide production using a mito-targeted reporter, MitoSOX
Red. Quantification of MitoSOX photometry revealed ~2.5-fold
increase in mitochondrial superoxide generation in APP mutant
cells and this was reduced by ~40% with NCLX expression
(Fig. 4j).
Having established that the restoration of mCa2+ efflux
capacity was sufficient to rescue OxPhos impairments and lessen
oxidative stress, we next considered the impact on Aβ production,
clearance, and toxicity. Western blot analysis in this model
recapitulated our in vivo rescue of NCLX (see Fig. 3m). Although
we found no change in total ADAM-10, or components of the γ-
secretase complex, we again noted a significant increase in
BACE1 expression in APPswe cells that was reduced with NCLX
expression (Fig. 4k; Supplementary Fig. 6R’). In addition, BACE1
activity was increased twofold in APPswe cells and the rescue of
NCLX expression reverted secretase activity back to control levels
(Fig. 4l). To further evaluate the effect of NCLX expression on Aβ
generation, we quantified extracellular Aβ1–40 and Aβ1–42 levels.
Compared with APPswe neurons we observed a ~40% decrease in
Aβ1–40 and Aβ1–42 formation in APPswe infected with Ad-NCLX
(Fig. 4m). As Aβ oligomerization significantly contributes to
aggregate formation we employed a fluorescent dye (ProteoStat)
to quantify intracellular amyloid-like aggregates. APPswe cells
displayed an abundance of intracellular aggregates (~14-fold over
control), whereas the rescue of NCLX expression returned protein
aggregation/inclusion body formation back to near control levels
(Fig. 4n, o). These results are intriguing and suggest that elevated
mCa2+ signaling/overload may contribute to the amyloid cascade.
mCa2+-overload has been suggested to augment neuronal cell
death, both through primary (MPTP and ROS) and secondary
signaling mechanisms (metabolic derangement, etc.)17,48. NCLX
expression was sufficient to reduce superoxide production and
MPTP activation and enhance OxPhos capacity, so next we tested
if these protective mechanisms coalesced to reduce neuronal
demise. Control, APPswe, and APPswe cells+Ad-NCLX were
treated with a variety of stressors associated with neurodegenera-
tion including: ionomycin (Ca2+ stress), glutamate (excitotoxi-
city), or tert-butyl hydroperoxide (TBH, ROS stress). Following
treatment with these stressors plasma membrane rupture (hall-
mark of cell death) and cellular viability were quantified. The
rescue of NCLX expression in AD cells significantly reduced cell
death and increased viability across multiple doses of all three
stressors tested (Fig. 4p, r and Supplementary Fig. 4A–C). These
results support that the rescue of mCa2+ efflux in the context of
AD may be a powerful therapeutic to impede cell loss and
neurodegeneration.
Rescue of mCa2+ efflux corrects mitochondrial dysfunction in
AD. To confirm our in vitro mechanistic findings, we measured
the CRC of mitochondria isolated from the frontal cortex of
12 month old mice as an indicator of susceptibility to MPTP
opening (Fig. 5a–d). 3xTg-AD mice (red arrow in representative
tracings) showed a significant reduction in CRC compared with
CamK2a-Cre controls (black arrow) (Fig. 5a, c). Accelerated loss
of neuronal NCLX in 3xTg-AD mice (blue arrow) greatly
decreased the CRC, suggesting 3xTg-AD × NCLX-cKO are more
sensitive to MPTP activation and loss of membrane potential
(Fig. 5a, b). Strikingly, the rescue of NCLX-dependent efflux sig-
nificantly reduced MPTP opening in 3xTg-AD mice (Fig. 5c, d).
Given that mCa2+ overload is often associated with increased
superoxide generation we performed DHE and 4-hydroxy-2-
nonenal (4-HNE) staining to evaluate redox stress46,49.
In agreement with our earlier findings the accelerated loss of
NCLX-dependent efflux in AD (3xTg-AD × NCLX-cKO)
increased superoxide production in freshly sectioned cortex
and hippocampal regions of the brain (Fig. 5e–g). In support,
the restoration of mCa2+ efflux capacity by neuronal NCLX
expression reduced AD-associated increases in superoxide
production (Fig. 5h–j). Quantification of lipid peroxidation,
oxidative degradation of lipids, by 4-HNE staining revealed a
~40% increase in 3xTg-AD × NCLX-cKO mice brains, as
compared with 3xTg-AD × Camk2a-Cre mice (Fig. 5k, l). We
noted a significant reduction in lipid peroxidation, indicative
of reduced oxidative stress, in 3xTg-AD × NCLX over-
expressing mice as compared with 3xTg-AD × Camk2a-tTA
mice (Fig. 5m, n).
mCa2+-overload and mitochondrial dysfunction could lead to
the activation of mitochondrial quality control pathways such as
autophagy. To determine whether the protective effect of
restoring NCLX expression in 3xTg-AD background was owing
to the preservation of mitochondrial mass we quantified the ratio
of mtDNA vs. nDNA, PGC1alpha mRNA expression, and citrate
synthase activity50. Employing three different assays we found no
change that would be indicative of a difference in mitochondrial
content associated with the genetic modulation of neuronal
NCLX (Fig. 5o, p; Supplementary Fig. 5A–D). We did observe a
slight age-dependent decrease in mitochondrial content, but again
this was independent of genotype.
Discussion
Here we report that AD is associated with a loss in expression and
functionality of the most prominent mCa2+ efflux transporter,
NCLX, resulting in severe impairments in mitochondrial function
and downstream signaling. The genetic rescue of NCLX expres-
sion in 3xTg-AD mice completely ablated age-associated cogni-
tive decline and significantly reduced neuronal pathology. While
previous reports have suggested a link between perturbed cCa2+
handling and mitochondrial dysfunction6,8,9, to date no studies
have directly examined the role of mitochondrial calcium sig-
naling in AD or have addressed if it plays a casual role in disease
progression. Postmortem AD brain pathology demonstrates
increased oxidative stress and metabolic derangement, which is
hypothesized to increase the vulnerability of neurons to excito-
toxicity and cell death51. We and others have previously reported
that impairments in mCa2+ exchange can significantly alter
metabolism and cell death20,22,52, both of which have been shown
to contribute to neurodegeneration13 through the activation of
various cell death pathways17,19. This paradigm fits with our
previous report18 where we found that impairments in mCa2+
exchange contributed to the development and progression of
heart failure, supporting that mCa2+ efflux is likely an important
contributor to cellular homeostasis and function in the context of
chronic disease.
There are several mechanisms by which Ca2+ has been linked
to neurodegenerative diseases. mCa2+ is known to cause OMM
permeability provoking the release of apoptogens53. Further,
mCa2+ is a central priming event in the opening of the mito-
chondrial permeability transition pore (MPTP) causing the col-
lapse of membrane potential and loss of ATP production,
resulting in necrotic cell death20. In support of the centrality of
this pathogenic mechanism, the inhibition of MPTP activation
using both pharmacological (cyclosporine-A and its derivatives)
and genetic means (CypD KO) reduces neuronal dysfunction and
degeneration in both cell culture and mutant mouse AD
models17,54. In agreement with this premise, Logan et al. 55.
reported that loss-of-function mutations in MICU1 (a negative
regulator of mtCU at low- /homeostatic cCa2+ levels) promotes
mCa2+ overload and is associated with severe brain and muscle
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disorders. These clinical results provide strong correlative evi-
dence that alterations in mCa2+ are linked with human disease. In
support of this notion, increased mCa2+ uptake via ERK1/2
dependent upregulation of MCU was recently reported to elicit
dendritic injury in a late-onset familial Parkinson’s disease (PD)
model (mutation in Leucine-Rich Repeat Kinase 2)56. Further, the
phosphorylation of NCLX by protein kinase A (PKA), which is
suggested to augment its activity, has been shown to reduce
mCa2+ load and enhance neuronal survival in a PINK-1 knock-
down cell line57. Other studies highlight the relationship between
mCa2+ dysregulation and alterations in ER and mitochondria
contact sites, which may also contribute to PD58 and AD
pathogenesis16,59. This is intriguing, as others have suggested that
Aβ mutations increase ER-mitochondrial contact16,59, which
could result in elevated ER to mitochondria Ca2+ transfer and
promote matrix-overload. In total, these studies support our
working hypothesis that mCa2+ homeostasis is disrupted in AD
leading to cellular dysfunction promoting a vicious pathological
cycle contributing to disease progression.
The observed mCa2+ dysregulation was associated with a sig-
nificant increase in mitochondrial superoxide generation and
impaired mitochondrial energetics. A number of studies have
shown that oxidative stress precedes Aβ accumulation and tau
phosphorylation46,49 and is an early indicator of AD. Oxidative
stress has also been shown to increase BACE1 expression, which
was likewise observed here60. In addition to oxidative stress61,
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Fig. 5 Restoration of mCa2+ efflux improves mitochondrial function in AD mutant mice. a Representative traces for mCa2+ retention capacity (CRC).
b Percent change in CRC of 3xTg-AD × Camk2a-Cre and 3xTg-AD × NCLXfl/fl × Camk2a-Cre vs. Camk2a-Cre control. c Representative trace for CRC in
Camk2a-tTA, 3xTg-AD × Camk2a-tTA and 3xTg-AD × TRE- NCLX × Camk2a-tTA mice. d Percent change in mCa2+ retention capacity of 3xTg-AD ×
Camk2a-tTA and 3xTg-AD × TRE- NCLX × Camk2a-tTA vs. Camk2a-tTA control. e DHE staining for ex vivo detection of superoxide production in freshly
prepared cortical and hippocampal sections from 12 months old mice. f, g DHE fluorescent intensity, percent change vs. 3xTg-AD × Camk2a-Cre controls.
h DHE staining for ex vivo detection of superoxide production in freshly prepared cortical and hippocampal sections from 12 months old mice. i, j
Quantification of DHE fluorescent intensity, percent change vs. 3xTg-AD × Camk2a-tTA controls. k Representative images of hippocampal 4-HNE
immunohistochemistry to detect lipid peroxidation in 12 months old mice. l Percent change in 4-HNE-integrated optical density area corrected to 3xTg-AD
× Camk2a-Cre controls. m Representative images of hippocampal 4-HNE immunohistochemistry to detect lipid peroxidation in 12 months old mice.
n Percent change in 4-HNE-integrated optical density area corrected with 3xTg-AD × Camk2a-tTA controls. oMitochondrial DNA (mtDNA)/nuclear DNA
(nDNA) ratio in tissue isolated from the cortex of 2 and 12 months old mice, fold change vs. 2 months old Camk2a-Cre controls. p mtDNA/nDNA ratio in
tissue isolated from the brain cortex of 2 and 12 months old mice expressed as fold change vs. 2 months old Camk2a-tTA controls. (n= individual dots
shown for each group in all graphs. All data presented as mean ± SEM; ****p < 0.001, **p < 0.01, *p < 0.05; one-way ANOVA with Sidak's multiple
comparisons test.) Source data are available as a Source Data file
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increased levels of BACE1 expression and tau hyperpho-
sphorylation have been reported during energy depletion62, and
mitochondrial stress conditions63. Therefore, it is intriguing to
surmise that mCa2+ overload and the associated oxidative stress
may form a maladaptive feed-forward loop with BACE1-mediated
amyloidosis. If correct, we may have uncovered another target to
inhibit the Aβ cascade, which is the predominant mechanism
thought to reduce synaptic dysfunction in AD64,65.
A few outstanding questions remain, such as why mCa2+ efflux
is downregulated early in the pathogenesis of AD. Our current
working hypothesis is that mCa2+ efflux is decreased and uptake
is increased in an attempt to elevate matrix Ca2+ content and
augment metabolic signaling, such as dehydrogenase activity, and
ATP production. This early compensatory response in the
metabolically challenged/stressed neuron then quickly turns
maladaptive due to mCa2+ overload and the sequella we report
here (Fig. 6). In addition, we were surprised that genetic altera-
tions in NCLX had no discernable impact on basal neuronal
function or behavior in young 2 months old mice given the
reported role of mitochondria to buffer Ca2+ at the synapse66,67.
We believe that perhaps the level of buffering required for
synaptic transmission remained intact in our model since we did
not alter MCU-mediated uptake and only enhanced efflux
capacity. While much work remains to unravel many of the
downstream mechanisms contributing to neurodegeneration in
AD, including the role of mtCU remodeling and mCa2+ uptake,
our study provides the first conclusive biological evidence that
loss of mCa2+ efflux accelerates AD development and that
enhancing the clearance of pathogenic mCa2+ may represent a
powerful therapy to reduce the progression of AD and other
neurodegenerative diseases.
Methods
Neuronal-specific NCLX knockout 3xTg-AD mutant mouse. NCLX floxed mice
were generated by our lab22 by acquiring targeted ES cells generated by recom-
binant insertion of a knockout-1st mutant construct containing loxP sites flanking
exons 5–7 of NCLX, Slc8b1 gene (ch12: 113298759- 113359493)68. ES cell lines
(clone EPD0460_4_A08, EUCOMM) were confirmed by PCR and injected into
C57BL/6N blastocysts with subsequent transplantation into pseudo- pregnant
females. Germline mutant mice were crossed with ROSA26-FLPe knock-in mice
for removal of the FRT-flanked splice acceptor site, βgal reporter, and neomycin
resistance cassette. Resultant NCLXfl/+ mice were interbred to generate homo-
zygous mutant mice with knockout potential (NCLXfl/fl). Homozygous LoxP
‘floxed’ mice (NCLXfl/fl) were crossed with neuron-specific Camk2a-Cre recom-
binase driver lines (available from Jackson Laboratory, stock no. 005359), resulting
in germline neuronal-specific deletion of NCLX. The Calcium/calmodulin-
dependent protein kinase II alpha (Camk2a) promoter drives Cre recombinase
expression in the forebrain, specifically to the CA1 pyramidal cell layer in the
hippocampus33. These mice were viable and fertile. Resultant neuronal-specific
loss-of-function models (NCLX-cKO- NCLXfl/fl Camk2a-Cre) were crossed with
3xTg-AD mutant mouse24 (available from Jackson Laboratory, stock no. 34830), to
generate 3xTg-AD × NCLXfl/fl × Camk2a-Cre (3xTg-AD × NCLX-cKO mice)
mutant mice. 3xTg-AD mice are homozygous for the Psen1 mutation (M146V
knock-in), and contain transgenes inserted into the same loci expressing the
APPswe mutation (APP KM670/671NL) and tau mutation (MAPT P301L). All
experiments involving animals were approved by Temple University’s IACUC and
followed AAALAC guidelines. All mice were maintained in our animal facility
under pathogen-free conditions on a 12 h light/12 h dark cycle with continuous
access to food and water.
Neuronal-specific NCLX overexpression 3xTg-AD mutant mouse. We cloned
the human NCLX sequence (NM_024959) (5′ EcoRI, 3′ XmaI) into a plasmid
containing the Ptight Tet-responsive promoter and a SV40 poly(A) sequence and
linearized the construct with Xhol digestion followed by gel and Elutip DNA
purification. Upon sequence confirmation the purified fragment was injected into
the pronucleus of a fertilized ovum and transplanted into pseudo-pregnant females
(C57BL/6N)22. Upon confirmation of germline transmission in founder lines,
mutant mice were crossbred with the Camk2a-tTA (neuronal-restricted expression,
doxycycline-off; Jackson Laboratory, stock no. 003010) transgenic model69. This
allowed conditional overexpression upon the withdrawal of chow containing
doxycycline (a tetracycline analog). Resultant neuronal-specific gain-of-function
model (TRE-NCLX × Camk2a-tTA) were crossed with 3xTg-AD mutant mouse to
generate 3xTg-AD × TRE-NCLX × Camk2a-tTA mutant mice. For all experiments,
mice were approved by Temple University’s IACUC following all AAALAC
guidelines.
Human AD tissue samples. Frontal cortex samples were collected postmortem
from non-familial AD patients and age-matched controls with no history of
dementia. These samples were provided by Dr. Domenico Praticò via the Arizona
State University (ASU) Brain bank. All tissue samples were rapidly frozen in liquid
nitrogen and stored at −80 °C until isolation of protein (n= 7 for non-familial,
sporadic AD and n= 7 for age-matched no history of dementia controls). Patient
consent, sample collection and preparation, and clinical data collection were per-
formed per a protocol approved by Temple University School of Medicine Insti-
tutional Review Board. Demographics of human samples are given in
Supplementary Table 1.
Cell cultures and differentiation. Mouse neuroblastoma N2a cell line as control
cells (N2a/con) and N2a cells stably expressing human APP carrying the K670N,
M671L Swedish mutation (APPswe) were grown in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin
(GIBCO) and in the absence (N2a/con) or presence of 400 µg/mL G418 (APPswe)
(Invitrogen Corporation) at 37 °C in the presence of 5% CO2. Before experiments,
APPswe cells were maintained to regular media without G418. In differentiation
studies, cells were grown in 50% Dulbecco’s modified Eagle’s medium (DMEM),
50% OPTI-MEM, 1% penicillin/streptomycin (GIBCO) for 72 hrs. Only cells with
passage number <20 were used. For all imaging studies, cells were plated on glass
coverslips pre-coated with poly-D-lysine. For overexpression of NCLX, we infected
maturated N2a Con and APPswe cells with adenovirus encoding NCLX (Ad-
NCLX) for 48 hrs.
qPCR mRNA analysis. RNA was extracted using the Qiagen RNeasy Kit. In brief,
1 µg of total RNA was used to synthesize cDNA in a 20 µL reaction using the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). qPCR analysis
was conducted following manufacturer instructions (Maxima SYBR, Thermo Sci-
entific). RPS13 was always used as an internal control gene to normalize for RNA.
Each sample was run in duplicate, and analysis of relative gene expression was
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Fig. 6 Working hypothesis of mCa2+ exchange dysfunction in AD
pathogenesis. Alzheimer’s disease (AD) initiators, such as aging and
metabolic dysfunction, elicit a compensatory increase in intracellular
calcium (iCa2+) and remodeling of the mCa2+ exchange machinery to
elevate matrix Ca2+ levels and activate mitochondrial dehydrogenases to
augment cellular energetics (blue boxes). However, these alterations in
iCa2+ handling quickly turn maladaptive leading to mCa2+-overload, which
results in mitochondrial dysfunction and AD pathophysiology. The
proposed sequence of events initiates positive feedback at multiple levels of
the disease pathway potentiating the progression of neurodegeneration
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calculated using the 2^ΔΔCt method. A list of all primer sequences can be found in
Supplementary Table 2.
Live-cell imaging of Ca2+ transients. Maturated neuronal cells were infected with
AAV6-mitoR-GECO to measure mCa2+ dynamics or loaded with the cytosolic Ca2+
indicator, 5 μM Fluo4-AM to study cytosolic Ca2+ dynamics. Cells were imaged
continuously in Tyrode’s buffer (150 mM NaCl, 5.4 mM KCl, 5 mM HEPES,
10 mM glucose, 2 mM CaCl2, 2 mM sodium pyruvate at pH 7.4) on a Zeiss 510
confocal microscope. Cells were treated with the depolarizing agent, 100 mM KCl,
to activate voltage-gated calcium channels during continuous live-cell imaging.
mCa2+ efflux rate was calculated as (Fmax/F0)−(Fend/F0)/sec and units expressed as
ΔF/sec and mCa2+ peak amplitude was calculated as (Fmax/F0)−(F0/F0). ΔF=
change in fluorescence intensity, F0= fluorescence intensity at 0 sec, Fmax=max-
imum fluorescence intensity, Fend= fluorescence intensity at the endpoint. Time
was presented in seconds.
Evaluation of mCa2+ retention capacity and content. To evaluate mCa2+
retention capacity (CRC) and content, N2a as con, APPswe and APPswe infected
with Ad-NCLX for 48 h were transferred to an intracellular-like medium con-
taining (120 mM KCl, 10 mM NaCl, 1 mM KH2PO4, 20 mM HEPES-Tris), 3 μM
thapsigargin to inhibit SERCA so that the movement of Ca2+ was only influenced
by mitochondrial uptake, 80-μg/ml digitonin, protease inhibitors (Sigma EGTA-
Free Cocktail), supplemented with 10 μM succinate and pH to 7.2. All solutions
were cleared with Chelex 100 to remove trace Ca2+ (Sigma). For mCa2+ retention
capacity: 2 × 106 digitonin-permeabilized neuronal cells were loaded with the
ratiometric reporters FuraFF at concentration of 1 μM (Ca2+). At 20 s JC1 (Enzo
Life Sciences) was added to monitor mitochondrial membrane potential (Δψ).
Fluorescent signals were monitored in a spectrofluorometer (Delta RAM, Photon
Technology Int.) at 340- and 380-nm ex/510-nm em. After acquiring baseline
recordings, at 400 s, a repetitive series of Ca2+ boluses (10 µM) were added at the
indicated time points. At completion of the experiment a protonophore, 10 μM
FCCP, was added to uncouple the Δψm and release matrix free-Ca2+. All
experiments (three replicates) were conducted at 37 °C. For mCa2+ content cells
from all the groups were loaded with Fura2 and treated with digitonin and thap-
sigargin20. Upon reaching a steady state recording, a protonophore, FCCP, was
used to collapse ΔΨ and initiate the release of all matrix free-Ca2+.
To examine mCa2+ retention capacity in vivo, mitochondria was isolated from
frontal cortex of 12 months old mice in mitochondria isolation buffer (225 mM
Mannitol, 75 mM Sucrose, 5 mM MOPS, 0.5 mM, 2 mM Taurine). Isolated
mitochondria were transferred to an intracellular-like medium containing
(120mM KCl, 10mM NaCl, 1 mM KH2PO4, 20mM HEPES-Tris) supplemented
with 10 μM succinate. In total, 200 µg mitochondria were loaded with the 1 μM
Calcium Green 5 N to monitor extra-mitochondrial Ca2+. Repetitive Ca2+ boluses
(5 µM) were added after baseline recordings at 400 s. Fluorescent signal at (488Ex/
530Em) was measured using plate reader. Inverse area under the curve was calculated
to measure percentage CRC after stepwise addition of 50 µm Ca2+ boluses.
Western blot analysis. All protein samples from brain or cell lysates were lysed by
homogenization in RIPA buffer for the soluble fractions and then in formic acid
(FA) for the insoluble fractions and used for western blot analyses. Samples were
run by electrophoresis on polyacrylamide Tris-glycine sodium dodecyl sulphate
gels. The following primary antibodies were used in the study: MCU dilution
1:1000 (Sigma-Aldrich, Catalog # HPA016480), MCUB dilution 1:1000 (Abgent,
Catalog #AP12355b), MICU1 dilution 1:500 (Custom generation by Yenzyme),
MICU2 dilution 1:1000 (Abcam, Catalog # ab101465), EMRE dilution 1:1000
(Santa Cruz, Catalog # sc-86337), NCLX dilution 1:500 (NCKX6 Santa Cruz,
Catalog # sc-161921), NCLX dilution 1:250 (Abcam SLC24A6, Catalog # ab83551),
VDAC dilution 1:2500 (Abcam, Catalog # ab15895), ETC respiratory chain com-
plexes dilution 1:5000 (OxPhos Cocktail, Abcam, Catalog # MS604), anti-APP N-
terminal raised against amino acids 66–81 for total APP 22C11 dilution 1:1500
(Chemicon International, Catalog # MAB348), BACE1 dilution 1:500 (Sigma,
Catalog # MAB5308), ADAM-10 dilution 1:500 (Chemicon International, Catalog
# AB19026), PS1 dilution 1:500 (Sigma- Aldrich, Catalog # S182), nicastrin dilution
1:200 (Cell Signaling, Catalog # 5665), APH1 dilution 1:200 (Millipore, Billerica,
MA, Catalog # AB9214), total tau HT7 dilution 1:200 (Thermo Fisher Scientific,
Catalog # MN1000), phospho-tau (pThr231) Monoclonal Antibody (AT180)
dilution 1:200 (Thermo Fisher Scientific, Catalog # MN1040), phospho-Tau
(Ser202, Thr205) monoclonal antibody (AT8) dilution 1:200 (Thermo Fisher Sci-
entific, Catalog # MN1020), phospho-tau (pThr181) antibody (AT270) dilution
1:200 (Thermo Fisher Scientific, Catalog # MN1050); phospho-tau (pS396) anti-
body (PHF13) dilution 1:200 (Cell Signaling, Catalog # 9632), beta-Tubulin dilu-
tion 1:1000 (Abcam, Catalog # ab6046) and Licor IR secondary antibodies dilutions
1:10,000 (LI-COR Biosciences, anti-mouse, Catalog # 925–68070; anti-rabbit,
Catalog # 926–32211; anti-goat, Catalog # 926–32214). All blots were imaged on a
Licor Odyssey system. All full-length western blots are available in Supplementary
Fig. 6. Densitometry of all the western blots are shown in Fig. S7.
Cognition function tests. Mice at 2, 6, 9, and 12 months of age were assessed for
behavioral test in the Y-maze and fear-conditioning assay.
Y-maze: In this test, mice were placed in the center of the Y-maze, and
allowed to explore freely through the maze during a 5-min session. This
apparatus consisted of three arms 32 cm (long) 610 cm (wide) with 26-cm walls.
The sequence and total number of arms entered were recorded. An entry into an
arm was considered valid if all four limbs entered the arm. An alternation was
defined as three consecutive entries in three different arms (i.e., 1, 2, 3, or 2, 3, 1).
The percentage alternation score was calculated using the following formula:
total alternation number/total number of entries-2) × 100. Furthermore, total
number of arm entries was used as a measure of general activity in the animals.
The maze was wiped clean with 70% ethanol between each animal to minimize
odor cues.
Fear conditioning: In brief, the fear-conditioning test was performed in a
fear-conditioning chamber equipped with black methacrylate walls, a
transparent front door, a speaker, and grid floor (Start Fear Systems; Harvard
Apparatus). During the training phase, each mouse was placed in the chamber
and underwent three cycles of 30 s of sound and 10 s of electric shock within a 6-
minute time interval. The next day, the mouse spent 5 min in the chamber
without receiving electric shock or hearing the sound (contextual recall). Two
hours later, the animal spent 6 min in the same chamber but with different
flooring, walls, smells, and lighting, and heard the cued sound for 30 s (cued
recall). Freezing activity of the mouse was recorded for each phase. The
formation of context fear is associated with the hippocampus and recall of
associations to cues is linked with the amygdala, therefore, we can assess
hippocampus and amygdala associated memory using this test. In this assay, if
the mouse remembers and connects the environment with the stimulus, it will
freeze, and freezing response is measured as a read-out.
Immunohistochemistry. Mouse brains were prepared for immunohistochemistry.
Serial 6-μm thick sections were deparaffinized, hydrated, and blocked in 2% fetal
bovine serum before incubation with primary antibody overnight at 4 °C. Sections
were incubated overnight at 4 °C with primary antibodies Aβ-4G8 (1:150 Covance),
HT7 (1:150), AT8 (1:50), 4-HNE (1:20; ab48506,) then incubated with secondary
antibody and developed using the avidin–biotin complex method (Vector
Laboratories, Burlingame, CA) with 3,3′diaminobenzidine as chromogen. 4G8
antibody is reactive to amino-acid residues 17–24 of Aβ and the epitope lies within
amino acids 18–22 of Aβ. 4G8 Aβ antibody reacts to abnormally processed iso-
forms, as well as precursors. The epitope for HT7 lies within amino acids 159–163
of tau.
Biochemical analysis. Mouse brain homogenates were sequentially extracted first
in RIPA for the soluble fractions and then in FA for the insoluble fractions. In brief,
30 mg of cerebral cortex were sonicated in RIPA buffer added with protease and
phosphatase inhibitors cocktail and subsequently ultracentrifuged at 90,720×g for
45 min. Supernatants were used to measure Aβ and tau soluble fractions by
enzyme-linked immunosorbent assay (ELISA) and western blotting, respectively.
Pellets were mixed in 70% formic acid, sonicated, neutralized in 6 N sodium
hydroxide, and used to measure Aβ and tau insoluble fractions by ELISA and
western. Aβ1–40 and Aβ1–42 levels were assayed by ELISA kit (Wako Chemicals
USA, Inc.). For in vitro analysis of Aβ1–40 and Aβ1–42 levels, conditioned media
from APPswe cells and cells infected Ad-NCLX were collected and analyzed at a
1:100 dilution using the method described in the manual (Wako Chemicals USA,
Inc.) as described previously70. Aβ1–40 and Aβ1–42 in samples were captured with
the monoclonal antibody BAN50, which specifically detects the N-terminal of
human Aβ(1–16). Captured human Aβ is recognized by another antibody, BA27 F
(Aβ’)2-HRP, a mAβ specifically detects the C-terminal of Aβ40, or BC05 F(Aβ’)2-
HRP, a mAβ specific for the C-terminal of Aβ42, respectively. HRP activity was
assayed by color development using TMB. The absorbance was then measured at
450 nm. Values were reported as a percentage of Aβ1–40 and Aβ1–42 secreted
relative to control.
Evaluation of ROS production. To measure the total cellular ROS, we employed
CellROX Green, a cell-permeable non-fluorescent (or very weakly fluorescent in a
reduced state) fluorogenic probes that exhibits a strong fluorogenic signal upon
oxidation. In this assay, cells were loaded with CellROX Green Reagent at a final
concentration of 5 μM for 30 min at 37 °C and measured the fluorescence at 485/ex
and 520/em using a Tecan Infinite M1000 Pro plate reader. To measure mito-
chondrial superoxide production cells were loaded with 10 μM MitoSOX Red for
45 min at 37 °C and imaged at 490/20ex and 585/40em. To monitor O2 generation,
cells from all groups was stained with 20 μM DHE for 30 min at 37 °C and imaged
on Carl Zeiss 510 confocal microscope at 490/20ex and 632/60em. For in vivo
detection of superoxide levels, cortical, and hippocampal slices were freshly pre-
pared from mice brains and stained with 20 μM DHE for 30 min at 37 °C and
imaged on a Carl Zeiss 710 confocal microscope. Images were quantified for
fluorescent optical density using ImageJ.
Mitochondrial bioenergetics. Control (N2a), APPswe, and Con, APPswe cells
infected with Ad-NCLX for 48 h were subjected to OCR measurement at 37 °C in
an XF96 extracellular flux analyzer (Seahorse Bioscience). Cells (3 × 104) were
plated in XF media pH 7.4 supplemented with 25 mM glucose and 1 mM sodium
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pyruvate and sequentially exposed to oligomycin (1.5 µM), FCCP(1 µM), and
rotenone plus antimycin A (0.5 µM). Quantification of basal respiration (base OCR
– non-mito respiration (post-Rot/AA), ATP-linked respiration (post-oligo OCR
−base OCR), Max respiratory capacity (post-FCCP OCR−post-Rot/AA), Spare
respiratory capacity (post-FCCP OCR−basal OCR) and Proton leak (post-Oligo
OCR−post-Rot/AA OCR) was performed.
Membrane rupture and cell viability assay. We evaluated membrane rupture
using SYTOX Green (Life Technologies) a membrane impermeable fluorescent
stain, which enters the cell upon membrane rupture, intercalates in DNA and
increases fluorescence > 500-fold. We examined general cell viability using Cell
Titer Blue (resazurin, Life Technologies). This Cell Titer Blue assay uses the
indicator dye resazurin to measure the metabolic capacity of cells. Viable cells
retain the ability to reduce resazurin into resorufin, which is highly fluorescent.
Nonviable cells rapidly lose metabolic capacity, do not reduce the indicator dye,
and thus do not generate a fluorescent signal. Equal numbers of N2a, APPswe
and APPswe infected with Ad-NCLX for 48 h were treated with Ionomycin,
(1–5 µM) for 24 h and an oxidizing agent TBH (10–30 µM) for 14 h and glu-
tamate (NMDAR-agonist, neuroexcitotoxicity agent) (10–50 µM) for 24 h. On
the day of the experiment, cells were loaded with 1 μM Sytox green for 15 min at
37 °C and measured the fluorescence at 504/ex and 523/em using a Tecan
Infinite M1000 Pro plate reader. Data are normalized to vehicle control to avoid
any differences in cell numbers between the groups.
β secretase activity assay. β-secretase activity was determined using fluorescent
transfer peptides consisting of APP amino-acid sequences containing the cleavage
sites of BACE secretase (BioVision). The method is based on the secretase-
dependent cleavage of a secretase-specific peptide conjugated to the fluorescent
reporter molecules EDANS and DAΒCYL, which results in the release of a fluor-
escent signal that was detected using a fluorescent microplate reader with excitation
wavelength of 355 nm and emission at 510 nm. The level of secretase enzymatic
activity is proportional to the fluorometric reaction, and the data is expressed as
fold increase in fluorescence over that of background controls. BACE1 activity was
assayed by a fluorescence-based in vitro assay kit according to the manufacturer’s
instructions (BioVision).
Detection of protein aggregates. For determination of misfolded protein
aggregates, cells were fixed with 4% paraformaldehyde at RT for 15 min and,
permeabilized in PBST (0.15% TritonX-100 in PBS) at RT for 15 min. Cells were
then stained with proteostat aggresome detection dye at RT for 30 min and
Hoechst 33342 nuclear stain, using the method described in the manual (Enzo
Life Science Inc., Farmingdale, NY, USA). Proteostat (Enzo), a molecular rotor
dye that becomes fluorescent when binding to the β-sheet structure of misfolded
proteins. All components of the proteostat aggresome detection kit were pre-
pared according to the manufacturer’s instructions. Aggregated protein accu-
mulation was detected using a Carl Zeiss 710 confocal microscope. (standard red
laser set for the aggresome signal and DAPI laser set for the nuclear signal
imaging). Further quantitative analyses, number of protein aggregates deposits
per cell were counted.
Quantification of mitochondrial copy number. To quantify mitochondrial copy
number, brain cortex tissue was homogenized, and total genomic DNA was iso-
lated using the DNeasy blood and tissue kit (Qiagen 69504) according to manu-
facturer’s instructions. Quantitative PCR (qPCR) quantification of mtDNA copy
number was performed using the primers directed against the mitochondrial
COXII gene and nuclear β-Globin using 100 ng of template DNA. For citrate
synthase activity assays please see Supplementary Methods in Supplementary
Information File.
Statistics. All results are presented as mean and ± SEM. Statistical analysis was
performed using Prism 6.0 (Graph Pad Software). All experiments were replicated
at least three times and measurements were taken on distinct samples. Individual
data points mean and s.e.m. were displayed in the figures. Where appropriate
column analyses were performed using an unpaired, two-tailed t test (for two
groups) or one-way ANOVA with Bonferroni correction (for groups of three or
more). For grouped analyses either multiple unpaired t-test with correction for
multiple comparisons using the Holm–Sidak method or where appropriate two-
way ANOVA with Tukey post hoc analysis was performed. P values < 0.05 (95%
confidence interval) were considered significant.
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available from the corresponding
author upon reasonable request. The source data underlying Figs. 1–5 and
Supplementary figures are provided as a Source Data file.
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